FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2977967558> ?p ?o ?g. }

• W2977967558 endingPage "e74" @default.
• W2977967558 startingPage "e68" @default.
• W2977967558 abstract "Abstract Background Angiogenesis is critical to gastroesophageal adenocarcinoma growth and metastasis. Regorafenib is a multikinase inhibitor targeting angiogenic and stromal receptor tyrosine kinases. We evaluated whether regorafenib augments the antitumor effect of first-line chemotherapy in metastatic esophagogastric cancer. Materials and Methods Patients with previously untreated metastatic gastroesophageal adenocarcinoma received 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) every 14 days and regorafenib 160 mg daily on days 4 to 10 of each 14-day cycle. The primary endpoint was 6-month progression-free survival (PFS). To identify predictive biomarkers of outcome, we examined correlations between genomic characteristics of sequenced pretreatment tumors and PFS. Results Between August 2013 and November 2014, 36 patients with metastatic esophagogastric cancer were accrued to this single-center phase II study (NCT01913639). The most common grade 3–4 treatment-related adverse events were neutropenia (36%), leucopenia (11%) and hypertension (8%). The 6-month PFS was 53% (95% confidence interval [CI], 38%–71%), the objective response rate was 54% (95% CI, 37%–70%), and the disease control rate was 77% (95% CI, 67%–94%). Next-generation sequencing did not identify any genomic alterations significantly correlated with response, and there was no association between homologous recombination deficiency and PFS with platinum-based chemotherapy. Conclusion Regorafenib (one week on–one week off schedule) is well tolerated in combination with first-line FOLFOX but does not improve 6-month PFS relative to historical control." @default.
• W2977967558 created "2019-10-10" @default.
• W2977967558 creator A5004669792 @default.
• W2977967558 creator A5009974709 @default.
• W2977967558 creator A5019892104 @default.
• W2977967558 creator A5019892202 @default.
• W2977967558 creator A5021215219 @default.
• W2977967558 creator A5031045426 @default.
• W2977967558 creator A5031805874 @default.
• W2977967558 creator A5033125884 @default.
• W2977967558 creator A5035865205 @default.
• W2977967558 creator A5036900549 @default.
• W2977967558 creator A5037092952 @default.
• W2977967558 creator A5038396374 @default.
• W2977967558 creator A5040211001 @default.
• W2977967558 creator A5042265453 @default.
• W2977967558 creator A5045756365 @default.
• W2977967558 creator A5053532132 @default.
• W2977967558 creator A5061301127 @default.
• W2977967558 creator A5068026508 @default.
• W2977967558 creator A5069929201 @default.
• W2977967558 creator A5074144766 @default.
• W2977967558 creator A5083619102 @default.
• W2977967558 creator A5087487609 @default.
• W2977967558 date "2019-09-30" @default.
• W2977967558 modified "2023-10-01" @default.
• W2977967558 title "Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer" @default.
• W2977967558 cites W1499992614 @default.
• W2977967558 cites W1893989035 @default.
• W2977967558 cites W1971837077 @default.
• W2977967558 cites W1979908884 @default.
• W2977967558 cites W2009337734 @default.
• W2977967558 cites W2019607817 @default.
• W2977967558 cites W2040007772 @default.
• W2977967558 cites W2050555289 @default.
• W2977967558 cites W2071069178 @default.
• W2977967558 cites W2080881382 @default.
• W2977967558 cites W2081367341 @default.
• W2977967558 cites W2091103707 @default.
• W2977967558 cites W2100439220 @default.
• W2977967558 cites W2104759721 @default.
• W2977967558 cites W2106157865 @default.
• W2977967558 cites W2111237964 @default.
• W2977967558 cites W2117564738 @default.
• W2977967558 cites W2118291530 @default.
• W2977967558 cites W2126547130 @default.
• W2977967558 cites W2147629880 @default.
• W2977967558 cites W2147834058 @default.
• W2977967558 cites W2155167083 @default.
• W2977967558 cites W2276228008 @default.
• W2977967558 cites W2318233342 @default.
• W2977967558 cites W2468218000 @default.
• W2977967558 cites W2472847770 @default.
• W2977967558 cites W2479891754 @default.
• W2977967558 cites W2532539628 @default.
• W2977967558 cites W2560322684 @default.
• W2977967558 cites W2560499218 @default.
• W2977967558 cites W2570401594 @default.
• W2977967558 cites W2613362156 @default.
• W2977967558 cites W2763064222 @default.
• W2977967558 cites W2767612092 @default.
• W2977967558 cites W2771217224 @default.
• W2977967558 cites W2796582438 @default.
• W2977967558 cites W2912403850 @default.
• W2977967558 cites W2947441361 @default.
• W2977967558 cites W2948169107 @default.
• W2977967558 cites W2964466303 @default.
• W2977967558 cites W2991564522 @default.
• W2977967558 doi "https://doi.org/10.1634/theoncologist.2019-0492" @default.
• W2977967558 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6964136" @default.
• W2977967558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31570517" @default.
• W2977967558 hasPublicationYear "2019" @default.
• W2977967558 type Work @default.
• W2977967558 sameAs 2977967558 @default.
• W2977967558 citedByCount "10" @default.
• W2977967558 countsByYear W29779675582020 @default.
• W2977967558 countsByYear W29779675582021 @default.
• W2977967558 countsByYear W29779675582022 @default.
• W2977967558 countsByYear W29779675582023 @default.
• W2977967558 crossrefType "journal-article" @default.
• W2977967558 hasAuthorship W2977967558A5004669792 @default.
• W2977967558 hasAuthorship W2977967558A5009974709 @default.
• W2977967558 hasAuthorship W2977967558A5019892104 @default.
• W2977967558 hasAuthorship W2977967558A5019892202 @default.
• W2977967558 hasAuthorship W2977967558A5021215219 @default.
• W2977967558 hasAuthorship W2977967558A5031045426 @default.
• W2977967558 hasAuthorship W2977967558A5031805874 @default.
• W2977967558 hasAuthorship W2977967558A5033125884 @default.
• W2977967558 hasAuthorship W2977967558A5035865205 @default.
• W2977967558 hasAuthorship W2977967558A5036900549 @default.
• W2977967558 hasAuthorship W2977967558A5037092952 @default.
• W2977967558 hasAuthorship W2977967558A5038396374 @default.
• W2977967558 hasAuthorship W2977967558A5040211001 @default.
• W2977967558 hasAuthorship W2977967558A5042265453 @default.
• W2977967558 hasAuthorship W2977967558A5045756365 @default.
• W2977967558 hasAuthorship W2977967558A5053532132 @default.
• W2977967558 hasAuthorship W2977967558A5061301127 @default.
• W2977967558 hasAuthorship W2977967558A5068026508 @default.

• next